Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
Lucid Diagnostics Inc (LUCD) PT Lowered to $2 at Cantor Fitzgerald
-
Cantor Fitzgerald Positive on Lucid Diagnostics Inc (LUCD) Following Earnings
-
Lucid Diagnostics Inc (LUCD) PT Lowered to $3.80 at Cantor Fitzgerald
-
PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference
-
PAVmed Provides Business Update and Third Quarter 2022 Financial Results
-
Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results
-
PAVmed PAVmed Provides Business Update and Preliminary First Quarter 2022 Financial Results
-
Lucid Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results
-
Cantor Fitzgerald Reiterates Overweight Rating, $12 Price Target on Lucid Diagnostics Inc (LUCD) on BeiGene's RATIONALE 306 Trial Data, "Encourage Investors to Acquire LUCD Shares at an Attractive Ent
-
PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
-
Cantor Fitzgerald Reiterates Overweight Rating and $12 PT on Lucid Diagnostics (LUCD), "We Encourage Investors to Acquire LUCD Shares at Attractive Valuation"
-
Lucid Diagnostics Inc (LUCD) Provides Business Update, Reports Prelim Q4
-
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
-
Cantor Fitzgerald Reiterates Overweight Rating on Lucid Diagnostics Inc (LUCD), Sees Launch in Three New Areas as Favorable and as an Important Commercialization Milestone
-
UPDATE: Cantor Fitzgerald Starts Lucid Diagnostics Inc (LUCD) at Overweight
-
Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering
-
Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering
-
Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering
-
Lucid Diagnostics Inc (LUCD) Prices 5M Share IPO at $14/sh
-
Lucid Diagnostics Announces Pricing of Initial Public Offering
-
Lucid Diagnostics Announces Pricing of Initial Public Offering
-
Lucid Diagnostics Announces Pricing of Initial Public Offering

